Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Immunotherapy is used to treat melanoma, however patient responses vary widely highlighting the need for factors that can predict therapeutic success. Here, the authors show that MHC-II molecules expressed by tumour cells are positively correlated with a good response to therapy and overall patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Douglas B. Johnson, Monica V. Estrada, Roberto Salgado, Violeta Sanchez, Deon B. Doxie, Susan R. Opalenik, Anna E. Vilgelm, Emily Feld, Adam S. Johnson, Allison R. Greenplate, Melinda E. Sanders, Christine M. Lovly, Dennie T. Frederick, Mark C. Kelley, Ann Richmond, Jonathan M. Irish, Yu Shyr, Ryan J. Sullivan, Igor Puzanov, Jeffrey A. Sosman, Justin M. Balko
Format: article
Language:EN
Published: Nature Portfolio 2016
Subjects:
Science
Q
Online Access:https://doaj.org/article/459810ce61c5459985557e37a55f8eed
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/459810ce61c5459985557e37a55f8eed

Similar Items